Product Code: 25EL-527-4035
Please note: This is a Single Viewer registration for one participant for the on-demand version of this program. Access instructions for the on-demand version of this program will be provided via email approximately 3-10 business days after the live program has occurred and the on-demand version is available. If registering after the on-demand version is available, immediate access is granted via the AABB Education Platform at https://education.aabb.org.
If you registered for the live program you do not need to register for this on-demand eCast (access to the on-demand eCast was included with the live program registration).
If you are interested in presenting this program to a group, please see the “eCast Registration Form– Group Viewing” form on the program page.
Program Description: For many patients with sickle cell disease (SCD), hematopoietic stem cell transplantation is unavailable due to lack of a matched donor. Gene therapy using autologous gene-edited stem cells has emerged as an option for these patients. Two gene therapy regimens have been approved by the FDA and additional clinical trials are underway. This program will provide background on gene therapy for SCD and an update on the status of SCD gene-editing clinical trials. The program will also address challenges in preparing products for patients enrolled in these trials and for the transfusion services providing transfusion support.
